News

Video

Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA Study

Author(s):

Alexander Spira, MD, PhD, FACP

A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.

Related Videos
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
Sandip P. Patel, MD
Alissa J. Cooper, MD
Related Content
FDA
September 12th 2024

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Danny Nguyen, MD
September 11th 2024

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Luis Raez, MD, of Memorial Cancer Institute
September 11th 2024

Timing of Immunotherapy Administration Is a Key Question to be Answered in Lung Cancer

Benjamin Besse, MD, PhD, a medical oncologist and professor of medicine at Paris Saclay University, Institut Gustave Roussy, Villejuif, France
September 11th 2024

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial